Announcements
03 February 2012
First Patient Enrolled for CANVAS >>
17 January 2012
Japanese Patent Granted for Cripto-1 Antibody >>
25 October 2011
Manufacturing Authorisation Granted in Germany >>
24 October 2011
Prima BioMed launches partnership with The City Hospital in Dubai Healthcare City to commercialise CVac™ in the Middle East >>
30 September 2011
Notice of 2011 annual general meeting >>
14 September 2011
Cvac Phase III CANVAS Ovarian Cancer Clinical Update >>
14 September 2011
Phase III CANVAS Update >>
12 September 2011
Patient Enrolment for Cvac Phase 11b Trial Complete >>
02 September 2011
Prima BioMed included in S&P Australian 300 Index >>
01 July 2011
Prima BioMed Investor Update >>
01 July 2011
Change to Place of Business & Resignation of Joint Company Secretary >>
28 June 2011
Prima Raises $20 Million in Share Purchase Plan >>
14 June 2011
Potency Assay for CVac Successful Development >>
31 May 2011
CVac Granted Approval in DHCC >>
30 May 2011
Share Purchase Plan Offer >>
26 May 2011
Prima Completes 21 Million Placement >>
25 May 2011
Prima Announces Plans to Raise 38Million >>
21 April 2011
Prima Awarded Japanese Patent >>
22 February 2011
Expert Call Webcast >>
21 February 2011
Regulatory Scientific Advice on CVac Phase III Trial >>
01 February 2011
Saftey Data Review Successful >>
11 January 2011
JP Morgan Healthcare Conference >>
10 January 2011
Springtree Early Termination of Facility >>
13 December 2010
Presentation Deutsche BioFest Conference >>
18 October 2010
Prima Presents at Cancer Immunotherapy Conference >>
07 October 2010
Inside Wall Street: Is This Tiny Aussie Biotech the Next Dendreon? >>
07 October 2010
Prima BioMed Appoints Lucy Turnbull as new Chairman >>
30 September 2010
Prima Plans to list on NASDAQ >>
20 September 2010
US FDA Grants Approval For CVac >>
27 August 2010
Preliminary Final Report >>
17 August 2010
Cripto-1 monoclonal antibody licensing with Bioceros >>
28 July 2010
Latest Update on CVac >>
23 July 2010
First Patient Phase IIb Trial >>
03 June 2010
European Orphan Drug Designation >>
27 May 2010
Partnership with Fraunhofer Institute >>
05 March 2010
EMEA Orphan Medicinal Product Designation >>
23 February 2010
Prima BioMed Completes SPP Short-Fall >>
22 February 2010
Half Year Report & Accounts >>
17 February 2010
Prima Appoints New CFO >>
05 February 2010
Commencement of CVac Ovarian Cancer Treatment Vaccine Phase >>
27 January 2010
Quarterly Activity Report 31 Dec 2009 >>
22 January 2010
Matthew Lehman Appointed New Chief Operating Officer >>
08 January 2010
JP Morgan Healthcare Conference US Jan 2010 >>
18 December 2009
Trial Starts on Ethics Approval >>
23 November 2009
Dr Neil Frazer appointed chief medicial officier to oversee >>
18 November 2009
To undertake research program to develop oral delivery system for cancer vaccine >>
22 October 2009
Prima BioMed secures japanese patent for Cancer Vac >>
16 October 2009
Share Purchase Plan Offer >>
|
|